Abstract. has been discovered to have anticancer properties in different tissues. However, the role of miR-206 on renal carcinoma is still ambiguous. In the present study, we investigated the role of miR-206 on the development of renal carcinoma. The results indicated that miR-206 was significantly downregulated in 69 clear cell renal carcinoma (ccRCC) tissues and low-level of miR-206 related to shorter metastasis-free survival time for patients with ccRCC. The results indicated that vascular endothelial growth factor A (VEGFA) was a direct target of miR-206 in renal cancer cells. Further studies revealed that upregulation of miR-206 inhibited renal cancer cell proliferation, invasion and migration, suggesting that miR-206 functioned as a tumor suppressor. RNA interference targeting VEGFA mRNA could mimic the upregulation of miR-206 functions, and also suppressed tumor formation in vivo in nude mice. These results suggest that miR-206 plays an important role in ccRCC tumorigenesis by targeting VEGFA.
Introduction
Renal cell carcinoma (RCC) is the most frequent form of kidney cancer, and clear cell RCC (ccRCC) represents the most common renal cancer histology (1) . The incidence and mortality rates of kidney cancer have increased in recent years, with an expected 63,920 newly-diagnosed cases and 13,860 deaths in 2014 worldwide (2) . Approximately one-third of RCC patients are diagnosed with metastatic disease and ~20-30% of subjects undergoing surgery would suffer recurrence (3, 4) . With the rapid development of target-agents blocking the vascular endothelial growth factor (VEGF) pathway or the mTOR pathway, a section of the patients with metastatic ccRCC can achieve a short-time durable remission (5) . However, the clinical evidence showed that various anti-VEGF agents have associated toxicity due to the disruption of normal vasculature (6, 7) . Angiogenesis is crucial for tumor growth and metastasis. Vascular endothelial growth factor A (VEGFA) has been identified as the predominant tumor angiogenesis factor in the majority of human cancers, including those of the renal, breast and colon cancer (8, 9) . However, the precise mechanisms for high VEGFA expression in human cancers are poorly understood in RCC. Therefore, it is highly critical to fully elucidate the underlying mechanism of RCC, which may contribute to the development of novel targeted therapies.
MicroRNAs (miRNAs) belong to a class of conserved endogenous non-coding small RNAs that negatively regulate gene expression at the post-transcriptional level by annealing with the 3'-untranslated region (3'-UTR) (10) . Critical roles of miRNAs have been demonstrated in various key biological processes including differentiation, development, proliferation and apoptosis. Recent studies have revealed that various miRNAs, such as miR-21, miR-34a, miR-141 and miR-200c, play a critical role in RCC progression (11) (12) (13) . ) is a member of the miR-1 family which includes miR-1, miR-133 and miR-206 (14) . miR-206/ miR-133b, miR-1b/miR-133a-1 and miR-1a/miR-133a-2 form clusters in three different chromosomal regions in the human genome 6p12.2, 18q11.2 and 20q13.33, respectively (15) . Previous studies have reported that the expression levels of miR-1 and miR-133a are significantly reduced in and correlated with RCC (16) . miR-206 was also reported to act as a tumor-suppressor in a variety of cancers. However, the biological roles and the exact mechanism of miR-206 in RCC are still poorly understood.
We identified downregulated miR-206 in ccRCC and explored its functions and mechanisms in ccRCC cells. We verified VEGFA as the direct functional target of miR-206 in ccRCC. These results verified that miR-206-VEGFA signaling pathways play an important role in renal carcinogenesis.
Materials and methods
Patients and clinical tissue specimens. Matched fresh ccRCC specimens and adjacent non-tumorous tissues (ANTs) were obtained from 69 clinically confirmed ccRCC patients after nephrectomy from the Peking Union Medical College Hospital (Table I) . Samples were immediately frozen and stored in liquid nitrogen prior to further processing. The present study was approved by the Human Ethics Committee of Peking Union Medical College Hospital. The collection and use of tissues followed procedures that are in accordance with the ethical standards as formulated in the Helsinki Declaration.
Cell culture and cell transfection. HEK-293T cells and human ccRCC cell lines ACHN and 786-O were obtained from the American Type Culture Collection. Primary culture of HK-2 human proximal convoluted tubule epithelial cells was obtained from the Shanghai Cell Bank, Chinese Academy of Sciences. All cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml of streptomycin. All cell lines were cultured at 37˚C in a humidified 5% CO 2 atmosphere.
miRNAs were transfected at a working concentration of 50 nM duplex using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. siRNA VEGFA and siRNA control were transfected at a final concentration of 40 nmol/l. The following siRNAs for VEGFA was used: VEGFA, 5'-UUCUCCGAACGUGUCAC GUTT-3'. The universal siRNA negative control that has no homology to any sequence in the human genome was used as a control. The following siRNA negative control sequence was used: 5'-AUAGGAGUAGUAGUAACAAUGUCGG-3' (sense). All RNA oligoribonucleotides were obtained from GenePharma (Shanghai, China).
Lentivirus production and transduction. The pri-miR-206 sequences were synthesized from normal human genomic DNA by PCR using primers: 5'-ATAAGAATGCGGCCGCA GATGCGGGCTGCTTCTGGA-3' (F) and 5'-AGCTTTG TTTAAACCCTTGGTGAGGGAGTCATTTGC-3' (R). The pri-miR-206 sequences cloned into pGLV-GFP vector (GenePharma). A lentiviral vector that expressed GFP alone (pGLV-control) was used as a control. Transfection of oligonucleotides or lentivirus construction was conducted with the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. 786-O cells were infected with the recombinant lentivirus-transducing units plus 5 mg/ml Polybrene (Sigma, USA).
RNA isolation and real-time PCR analysis. Total RNA was extracted from cells and tissues using TRIzol (Invitrogen) according to the instructions of the manufacturers. VEGFA expression levels were quantified using SYBR ® Premix Ex Taq II (Takara, Japan); β-actin was used as the reference gene. miR-206 expression was quantified using the Hairpin-it™ Real-Time PCR kit (GenePharma); U6 was used as an internal standard. qRT-PCR was performed on the ABI Prism 7500 Fast Sequence Detection System (Applied Biosystems). Levels of relative expression were calculated and quantified with the Data are expressed as n (%). BMI, body mass index.
Renilla luciferase gene. The results are presented as the ratio of Renilla luciferase activity to firefly luciferase activity.
Cell proliferation analysis. The cell proliferation assays were conducted using a Cell Counting Kit-8 (CCK-8; Dojindo Laboratories, Japan) according to the manufacturer's instructions. The cells were seeded into 96-well plates at ~5,000 cells/well and cultured in growth medium. A 10 µl of CCK-8 was added to 90 µl of culture medium at the indicated time. Subsequently, the cells were incubated at 37˚C for 2 h and the optical density was measured at 450 nm.
Colony formation assays. For the colony formation assay, 500 cells were placed in each well of a 6-well plate and incubated at 37˚C for 2 weeks. Colonies were fixed and stained in a dye solution containing 0.1% crystal violet and 20% methanol. The number of colonies was counted under a microscope.
Cell cycle analysis. Cells were synchronized with serum deprivation for 48 h and then released into the S phase by the re-addition of serum. Cells were collected and fixed in ice-cold 70% ethanol overnight. Before staining, the cells were spun down in a cooled centrifuge and resuspended in cold phosphate buffered solution. RNAase was added at a final concentration of 100 µg/ml, and cells were incubated at 37˚C for 30 min, followed by incubation in 50 µg/ml of propidium iodide (both from Sigma) for 20 min at 4˚C. For each sample, at least 10 4 cells were analyzed using FACS cytometry (Becton-Dickinson) and ModFit Ⅱ software. Twenty thousand cells were analyzed on a flow cytometer (FACSCalibur; BD Biosciences, USA).
Apoptosis analysis. Apoptosis was evaluated by Annexin V and 7-AAD binding assay using the PE Annexin V apoptosis detection kit I (BD, USA) according to the manufacturer's instructions. At least 1x10 6 cells in each sample were analyzed. Control cells stained with Annexin V-PE or 7-AAD alone were used as NCs for the flow cytometric analysis.
Transwell migration and Matrigel invasion assays.
Transwell chambers precoated with Matrigel (BD Biosciences) were used to perform the Matrigel invasion assay. Cells were cultured in serum-free medium in the upper chambers of the Transwell insert (5x10 4 cells/chamber), which are separated from the lower chambers with permeable 8 mm polycarbonate membranes. Medium containing 10% FBS served as the attractant in the lower chambers. After 12 h, the cells were fixed with 75% ethanol and stained with crystal violet. The Transwell migration assays were performed in a similar manner as the Matrigel invasion assays, but without Matrigel on the filter. All experiments were performed in triplicate and were repeated once.
Western blot analysis. Proteins were extracted from human renal cancer tissues or subconfluent culture of cells, and were then characterized using western blot analysis. Total protein concentration was determined with Bio-Rad Protein Assay Dye Reagent Concentrate (Bio-Rad, USA). Protein samples were separated on a 10% SDS-PAGE gel, transferred to polyvinylidene defluoride (PVDF) membranes, and probed with rabbit polyclonal antibodies to VEGFA (1:1,000) or GAPDH (1:5,000) (both from Cell Signaling Technology, USA) overnight at 4˚C. After extensive washing, the membrane was incubated with secondary antibody conjugated with horseradish peroxidase (1:10,000; Cell Signaling Technology) for 1 h at room temperature. Blots were developed using ECL (PE Life Sciences, USA). The optical intensity of each protein staining was determined using Quantity One software. Statistical analysis. The statistical analyses were performed with SPSS 19.0 software (SPSS, Inc., Chicago, IL, USA). Data are expressed as the mean ± standard deviation (mean ± SD) from three separate experiments. Statistical significance was determined by paired or unpaired Student's t-test in cases of standardized expression data. The Kaplan-Meier method was used to estimate and compare the probability of metastasis-free survival. Multivariate survival analysis was performed on all significant parameters from the univariate analysis using the Cox regression model. p<0.05 was considered to indicate a statistically significant result.
Tumorigenicity in vivo.

Results
miR-206 is downregulated in ccRCC and low miR-206
expression is associated with ccRCC metastasis. To determine whether miR-206 is downregulated in ccRCC tissues, we quantified the expression levels of miR-206 in 69 pairs of human ccRCC tissues and ANTs by qRT-PCR (Fig. 1A) . The relative expression of miR-206 was normalized to an endogenous control (U6 RNA). Furthermore, miR-206 expression was significantly lower in metastatic ccRCC than that in ccRCC samples without metastasis in the 6-year observational period after nephrectomy (Fig. 1B) . In addition, ccRCC cell lines (786-O and ACHN) showed significantly lower miR-206 expression compared to HK-2 cells (Fig. 1C) . The median expression level of all 69 ccRCC tissues was chosen as the cut-off point for separating tumors with low miR-206 expression from those with high expression. Overall, 34/69 ccRCC samples exhibited low miR-206 expression, whereas 35/69 showed high expression. The Kaplan-Meier analysis revealed that low miR-206 expression in ccRCC was associated with shorter metastasis-free survival (p=0.0143; Fig. 1D ). Table II , expression of miR-206 and VEGFA was associated with distant metastasis (p=0.020, p<0.001, p=0.027 and p=0.003, respectively) in univariate analysis and multivariate analysis. Similarly, pT stage showed statistical significance (p<0.001 and p=0.004). However, the age, gender, body mass index (BMI), Fuhrman grades, histological necrosis and sarcomatoid feature, were not associated with metastasis in this model. Fig. 2A) , and restoration of miR-206 caused a substantial reduction in colony formation compared with the control group (Fig. 2B) . To further characterize the effect of miR-206 on the cell cycle, we analyzed the cell cycle distribution in transfected cells by flow cytometry. The miR-206 mimics caused significant G 0 /G 1 arrest Table II . Univariate and multivariate analysis of factors associated with metastasis-free survival time of RCC patients. in 786-O and ACHN cells (Fig. 2C) . Next, we used FACS analysis to examine the effects of miR-206 on apoptosis. Cells transfected with miR-206 mimics showed an increase in early and late apoptotic cells in ccRCC cell lines (Fig. 2D) . We performed Transwell migration and Matrigel invasion assays to study the potential effect of miR-206 in ccRCC cell (Fig. 2E) . These results suggest that miR-206 restoration suppresses proliferation and metastasis in vitro.
Effect of miR-206 restoration on cell proliferation, invasion and migration in ccRCC cell lines. CCK-8 results showed that miR-206 caused a remarkable inhibition of cell growth in both 786-O and ACHN cells (
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VEGFA is the direct downstream target of miR-206.
To further unravel the mechanism by which miR-206 inhibits renal carcinogenesis, we searched for potential mRNA targets of miR-206 by the online bioinformatics TargetScan algorithm. VEGFA stood out as an attractive candidate since it is a promising proto-oncogene involved in multiple cancer-related pathways.
To determine whether VEGFA is the direct target gene for miR-206, a dual-luciferase reporter system was developed. The luciferase reporter assay indicated that the luciferase activity of the reporter containing the VEGFA gene's wide-type 3'-UTR decreased significantly following treatment with miR-206 mimics. By contrast, the inhibitory effect of the miR-206 mimics was abolished in the mutated construct ( Fig. 3A and B) . The result indicates that miR-206 most likely suppresses gene expression through miR-206-binding sequences at the 3'-UTR of VEGFA. In addition, qRT-PCR and western blot analysis revealed that the expression of VEGFA mRNA and protein was inhibited by treatment with miR-206 mimics in 786-O and ACHN cells (Fig. 3C and D) . Furthermore, the expression of VEGFA and protein in the tumor tissues was upregulated compared with paired adjacent non-tumor tissues (Fig. 3E) . Analysis of the correlation of miR-206 and VEGFA levels showed that the level of VEGFA is inversely correlated with the level of miR-206 in renal cancer tissues (Fig. 3F) . Taken together, these results supported the hypothesis that VEGFA is the direct target of miR-206 in ccRCC.
Effect of VEGFA silencing on cell proliferation, invasion and migration in ccRCC cell lines.
To examine the functional role of VEGFA, we performed loss-of-function studies in 786-O and ACHN cell lines transfected with siRNA-VEGFA (si-VEGFA). The mRNA and protein expression levels of VEGFA were markedly repressed by these si-VEGFA transfections ( Fig. 4A and B) . The CCK-8 assay revealed significant inhibition of cell proliferation in si-VEGFA transfectants in comparison with the siRNA-NC transfectants (Fig. 4C) . Downregulated VEGFA by si-VEGFA caused a substantial reduction in colony formation compared with the control group (Fig. 4D) . Flow cytometry also demonstrated significant G 0 /G 1 arrest (Fig. 4E ) and increased apoptotic cells (Fig. 4F ) in si-VEGFA transfectants compared with the counterparts. Transwell migration and Matrigel invasion assays were performed to assess the potential effect of VEGFA silencing in ccRCC cell lines. Inhibition of VEGFA suppressed the migra- (Fig. 4G) .
miR-206 inhibits tumor growth tumorigenicity in vivo.
To further confirm the negative roles of miR-206 in tumor growth (Fig. 5A ) and qRT-PCR was used to confirm upregulation of miR-206 (Fig. 5B) . Next, 786-O cells infected with pGLV-miR-206 or pGLV-control were subcutaneously injected into the flanks of nude mice with 1x10 7 cells in 0.2 ml at each site. Four weeks after inoculation, the nude mice were sacrificed and tumors were excised and measured. The results showed that tumor sizes and weights were significantly decreased in the pGLV-miR-206 group compared to the pGLV-control group (Fig. 5C and D) .
Discussion
Dysregulation of miRNAs has been demonstrated to contribute to RCC tumorigenesis. Evidence of miR-206 as a tumor growth suppressor has been reported in a variety of cancers, including pancreatic adenocarcinoma, rhabdomyosarcoma, lung and gastric cancer (16, (18) (19) (20) . miR-206 inhibits malignant transformation and cancer progression by negatively regulating proto-oncogenes, including c-MET, Notch3, ANXA2 and KRAS. Previous study revealed that miR-206 was downregulated in RCC clinical specimens (17) , however, little is known concerning the exact mechanism of miR-206 in ccRCC. In our study, we demonstrated that the miR-206 levels in renal cancer tissues are significantly lower than those in noncancerous tissues by qRT-PCR. Furthermore, the low-level of miR-206 also indicated a higher probability of developing metastasis and was related to metastasis-free survival time. In addition, the restoration of miR-206 suppresses cell proliferation and metastasis in vitro. Finally, the growth inhibitory effect was observed by nude mouse xenograft assays, indicating that miR-206 is crucial for human ccRCC tumorigenesis.
VEGF can significantly promote endothelial cell division, proliferation and migration. It also plays an important role in tumor angiogenesis thus has been an attractive target for both cancer diagnosis and therapy (21) . The previous cumulative evidence suggested that increased VEGF expression may contribute to RCC development and high level of VEGFA is related to poor prognosis and metastasis of RCC (9) . In our study, we also found similar results that high level of VEGFA expression associated with shorter metastasis-free survival time.
Various anti-VEGF monoclonal antibodies and oral VEGFR inhibitors that specifically bind to VEGF receptor and inhibit its tyrosine kinase activity have been under clinical development for the treatment of ccRCC. However, increasing number of clinical trials have confirmed that various anti-VEGF agents are associated with adverse effects that impair quality of life, such as neutropenia, thrombocytopenia, hyperamylasemia, diarrhea, hand-foot syndrome and hypertension (6) (7) 22) . Therefore, these therapeutic strategies need to be improved to reduce side-effects and research on alternative innovative therapeutic strategies are required for RCC therapy. Thus, the endogenous miRNA provides an alternative clue for anti-VEGF treatments. In the present study, we identified VEGFA as a target of miR-206 and revealed a novel function of miR-206 in suppressing proliferation and metastasis via direct target 3'-UTR of VEGFA. Luciferase assays and western blotting demonstrated that VEGFA is a target of miR-206 in ccRCC cell lines. In addition, we found that the level of miR-206 is negatively correlated with VEGFA expression in renal cancer tissues. In agreement with our findings, it has been recently reported that miR-206 modulates vasculature formation during developmental angiogenesis via VEGFA (23) . Furthermore, siRNA interference of VEGFA could mimic the miR-206 functions, inhibiting ccRCC cell proliferation, invasion and migration. Therefore, identification of VEGFA as a direct target for miRNA-206 may imply that miRNA-206 is a novel target for ccRCC therapy. In summary, we have identified that miR-206 acts as a tumor suppressor and is related to metastasis-free survival time of ccRCC patients. Introduction of miR-206 into ccRCC cell lines leads to inhibition of cell proliferation and metastasis by directly targeting 3'-UTR of VEGFA. Hence, our data suggest that miR-206 may have therapeutic value for the future management of ccRCC patients.
